FNTB and triple-negative breast carcinoma: FNTB genotyping was performed by pyrosequencing in 797 patients from a representative cohort of non-metastasized early breast cancer patients (51.7% pT1, 42.9% pT2, 4.6% pT3, 0.8% pT4; 76% luminal, 13.9% HER2-positive, 10% triple negative breast cancer, TNBC), recruited in the prospective multicentre observational PiA trial (NCT 01592825).